Popular
‘It haunts me daily:’ Freed Israeli hostages fear...
‘What is it if not a war crime?’...
Netanyahu says Israel killed elusive Hamas leader Mohammed...
Top Kremlin aide says Trump ‘not sufficiently informed’...
French doctor accused of sexually abusing hundreds of...
The Best Five Sectors, #20
Is It A Pullback? Or is More Downside...
Mixed Signals on the Charts? RRG Reveals Market...
Smarter Options Trading Starts Here! StockCharts + OptionsPlay
Larry Williams on the Fed, Interest Rates &...
  • Home
HotInvestingPilots.com
  • Politics
  • World News
  • Stock
  • Investing
Investing

Successful Completion of Placement to Accelerate Clinical Programs

by March 4, 2025
written by March 4, 2025

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce that it has successfully completed a new share placement (Placement) to raise $2.0 million to advance research and development in Photosoft as a potential treatment for a range of cancers.

Highlights:

  • Invion raises $2M via a share placement with the new shares priced at $0.14, a 2.5% premium to the 30-day VWAP and nil discount to last closing price
  • Investors in the placement will also receive one unquoted three-year option (exercise price of $0.28) for every new share
  • Proceeds from the placement will be used to:
    • Recruit from a second site for Invion’s Phase I/II skin cancer trial
    • Initiate a Phase I/II anogenital trial with the Peter MacCallum Cancer Centre
    • Fund general working capital
  • A successful outcome in the anogenital trial may enable orphan drug designation in the US to fast-track trials in the rare disease indication(s)
  • Multiple milestones on the horizon, including:
    • Results from the skin cancer trial
    • Initiation & progress on the anogenital trial
    • Updates on the glioblastoma, oesophageal cancer and HPV studies that are fully funded by Invion’s partners

The offer price for the new shares of $0.14 per share represents a 2.5% premium to the 30-day volume-weighted average price (VWAP) and a zero discount to its last closing price before the Placement announcement on 27 February 2025.

The lead manager for the Placement, Blue Ocean Equities (Lead Manager), received strong demand for the Placement, which was originally seeking to raise $1.5 million from sophisticated investors.

The Placement will comprise of two tranches:

  • Tranche 2: Placement of the balance of shares, conditional on the Company obtaining shareholder approval at the Extraordinary General Meeting (EGM) expected to be held in April 2025.

Investors in the placement will receive one unquoted attaching option for each new share with an exercise price of $0.28 and will expire three years from issue, subject to shareholder approval at the EGM.

The Lead Manager is to receive a capital raising fee of 6% on the proceeds of the Placement and will also receive a tranche of options to an equivalent value of approximately $80,000 using a Black Scholes options pricing formula with the following inputs:

  • Exercise price – each option will have an exercise price which is a 50% premium to the 15-day VWAP calculation as at the date of the placement.
  • Expiry – the options will expire 2 years from the date of issuance.
  • Volatility rate – 100%.
  • Risk Free Rate – 5%.

The Company will lodge an appendix 3B with the ASX with these details as soon as the number of options has been calculated. These issue of these options is subject to the approval of shareholders at the EGM.

Use of Proceeds from the Placement

Proceeds from the raise will be used to recruit from a second clinical site for Invion’s Phase I/II non-melanoma skin cancer (NMSC) trial, initiate a Phase I/II anogenital trial with the Peter MacCallum Cancer Centre (Peter Mac) and for general working capital.

Invion plans to leverage the safety data from the NMSC trial to accelerate a pathway to the anogenital trial as both trials are using the same topical formulation of INV043. Anogenital cancers include penile, vulva and anal cancers, which are rare diseases.

A successful outcome in the anogenital trial may enable orphan drug designation with the U.S. Food & Drug Administration (FDA). The granting of an orphan drug designation will give Invion a faster and more cost-effective path to commercialise Photosoft for the treatment of the rare disease(s) in question.

Thian Chew, Invion’s Executive Chair and CEO, commented:

“We are delighted to welcome new shareholders to Invion via the Placement, many of whom are sophisticated investors in the biotech space that are supporting the Company after reviewing our achievements and the multiple milestones in our horizon.

“In addition to the skin and anogenital cancer trials, these milestones also include updates on the glioblastoma, oesophageal cancer and human papilloma virus studies that are fully funded by our partners.”

This announcement was approved for release by Invion’s Board of Directors.

Click here for the full ASX Release

This post appeared first on investingnews.com

0 comment
0
FacebookTwitterPinterestEmail

previous post
Hempalta Corp. Announces Financial Results for Three Months Ended December 31, 2024
next post
High Resolution Ground Magnetics Commences at 100% – Owned Kiabye Gold Project, Western Australia

Related Articles

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies

May 28, 2025

ARR advances permitting at Cowboy State Mine

May 28, 2025

Investment Protection Agreement with the Ecuador Government on...

May 28, 2025

Phase 1 Drill Program – Operational and Geological...

May 28, 2025

WESTERN COPPER FORMALLY EXTENDS INVESTOR RIGHTS AGREEMENT WITH...

May 28, 2025

Crypto Market Review: Trump Media Planning US$3 Billion...

May 27, 2025

FPX Nickel and JOGMEC Initiate Exploration at the...

May 27, 2025

Cardiol Therapeutics to Webcast Virtual Annual General Meeting...

May 27, 2025

Bitcoin Well Announces Nostr Integration; Including Bitcoin Purchases...

May 27, 2025

Blue Sky Uranium: Argentina’s Emerging Uranium Resource Developer

May 27, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • ‘It haunts me daily:’ Freed Israeli hostages fear for those still held captive by Hamas

    May 28, 2025
  • ‘What is it if not a war crime?’ Former Israeli PM blasts war in Gaza

    May 28, 2025
  • Netanyahu says Israel killed elusive Hamas leader Mohammed Sinwar in recent Gaza strike

    May 28, 2025
  • Top Kremlin aide says Trump ‘not sufficiently informed’ about Ukraine after US president lashes out at Putin

    May 28, 2025
  • French doctor accused of sexually abusing hundreds of children is sentenced to 20 years

    May 28, 2025
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 hotinvestingpilots.com | All Rights Reserved

HotInvestingPilots.com
  • Politics
  • World News
  • Stock
  • Investing